MOOD — Doseology Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$4.43m
- CA$3.50m
- CA$0.10m
- 53
- 10
- 60
- 35
Annual income statement for Doseology Sciences, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.016 | 0.043 | 0.099 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -0.148 | 0.041 | 0.072 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.432 | 1.56 | 1.88 | 0.864 | 0.464 |
| Operating Profit | -0.432 | -1.56 | -1.87 | -0.821 | -0.365 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.432 | -1.63 | -1.94 | -1.78 | -0.34 |
| Net Income After Taxes | -0.432 | -1.63 | -1.94 | -1.78 | -0.34 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.432 | -1.63 | -1.94 | -1.78 | -0.34 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.432 | -1.63 | -1.94 | -1.78 | -0.34 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.123 | -0.442 | -0.482 | -0.398 | -0.082 |